Keyphrases
Highly Effective
100%
Triple-negative Breast Cancer
100%
Pro-survival
100%
Preclinical Trials
100%
Simultaneous Targeting
100%
Patient-derived Xenograft
100%
HER Family
100%
Antibody Mixtures
100%
Pan-HER
100%
Breast Cancer Patients
57%
Tumor
42%
HER3
28%
Patient-derived Tumor Xenograft
28%
Signaling Pathway
14%
Response to Therapy
14%
Protein Level
14%
Tumor Samples
14%
Western Blot Analysis
14%
Monoclonal Antibody
14%
Therapeutic Potential
14%
Human Epidermal Growth Factor Receptor 2 (HER2)
14%
Cancer Cells
14%
Potential Therapeutics
14%
Immunohistochemical Analysis
14%
Tumor Growth
14%
Breast Cancer Cases
14%
Intraperitoneal Injection
14%
Engraftment
14%
Tumor Regression
14%
Vehicle Control
14%
Resistance Development
14%
Human Epidermal Growth Factor Receptor
14%
Downmodulation
14%
RNA Analysis
14%
End of Treatment
14%
Denmark
14%
Mammary Fat Pad
14%
Low Passage
14%
Cancer Clinical Trials
14%
Family Activation
14%
Formulation Buffers
14%
Medicine and Dentistry
Xenograft
100%
Triple Negative Breast Cancer
100%
Epidermal Growth Factor Receptor
57%
Clinical Trial
14%
Neoplasm
14%
Immunohistochemistry
14%
Tumor Progression
14%
Tumor Model
14%
Monoclonal Antibody
14%
Gamma Urogastrone
14%
Western Blot
14%
Cancer Cell
14%
Tumor Xenograft
14%
Buffer
14%
Cancer Treatment
14%
Cell Signaling Pathway
14%
Fat Pad
14%
Engraftment
14%
Tumor Regression
14%
Protein Kinase B
14%
Intraperitoneal Drug Administration
14%
Tumor
14%
Nursing and Health Professions
Triple Negative Breast Cancer
100%
Xenograft
100%
Epidermal Growth Factor Receptor
57%
Neoplasm
14%
Western Blotting
14%
Immunohistochemistry
14%
Malignant Neoplasm
14%
Monoclonal Antibody
14%
Tumor Growth
14%
Buffer
14%
Tumor Regression
14%
Intraperitoneal Drug Administration
14%
Engraftment
14%
Gamma Urogastrone
14%
Tumor Model
14%
Tumor Xenograft
14%
Protein Kinase B
14%
Pharmacology, Toxicology and Pharmaceutical Science
Triple Negative Breast Cancer
100%
Epidermal Growth Factor Receptor
57%
Neoplasm
28%
Clinical Trial
14%
Malignant Neoplasm
14%
Western Blot
14%
Tumor Growth
14%
Monoclonal Antibody
14%
Protein Kinase B
14%
Intraperitoneal Injection
14%
Buffer
14%
Tumor Regression
14%
Tumor Model
14%
Gamma Urogastrone
14%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Clinical Trial
25%
RNA
25%
Monoclonal Antibody
25%
Western Blot
25%
Cancer Cell
25%
Protein Kinase B
25%
Tumor Progression
25%